Visual outcome measures in clinical trials of remyelinating drugs

One of the most promising approaches to delay, prevent or reverse disability progression in multiple sclerosis (MS) is to enhance endogenous remyelination and limit axonal degeneration. In clinical trials of remyelinating drugs, there is a need for reliable, sensitive and clinically relevant outcome...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ neurology open Jg. 6; H. 1; S. e000560
Hauptverfasser: Riboni-Verri, Gioia, Chen, Benson S, McMurran, Christopher E, Halliwell, Gregory J, Brown, J William L, Coles, Alasdair J, Cunniffe, Nick G
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England BMJ Publishing Group Ltd 19.02.2024
BMJ Publishing Group LTD
BMJ Publishing Group
Schlagworte:
Biomarkers
CLINICAL NEUROLOGY
Clinical trials
MULTIPLE SCLEROSIS
MYELIN
NEUROOPHTHALMOLOGY
Pathology
Radiation
Review
Tomography
VISUAL EVOKED POTENTIALS
MYELIN
NEUROOPHTHALMOLOGY
MULTIPLE SCLEROSIS
CLINICAL NEUROLOGY
VISUAL EVOKED POTENTIALS
ISSN:2632-6140, 2632-6140
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:One of the most promising approaches to delay, prevent or reverse disability progression in multiple sclerosis (MS) is to enhance endogenous remyelination and limit axonal degeneration. In clinical trials of remyelinating drugs, there is a need for reliable, sensitive and clinically relevant outcome measures. The visual pathway, which is frequently affected by MS, provides a unique model system to evaluate remyelination of acute and chronic MS lesions in vivo and non-invasively. In this review, we discuss the different measures that have been used and scrutinise visual outcome measure selection in current and future remyelination trials.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2632-6140
2632-6140
DOI:10.1136/bmjno-2023-000560